Frontotemporal Dementia Clinical Trials 2023

What are the top hospitals conducting frontotemporal dementia research?

Frontotemporal dementia, a complex neurodegenerative condition affecting the frontal and temporal lobes of the brain, has spurred top hospitals across the United States to spearhead groundbreaking clinical trials. In Philadelphia, the University of Pennsylvania leads with an impressive seven active trials focused on frontotemporal dementia, accompanied by a total of 23 trials in their journey thus far. Their pioneering efforts began back in 2003 when they recorded their first trial dedicated to understanding this debilitating disease. Similarly committed to advancing research is Mayo Clinic in Rochester, where six ongoing clinical trials are shedding light on frontotemporal dementia. With a history encompassing 15 previously conducted studies since their inaugural trial in 2008, Mayo Clinic continues to push boundaries and expand our knowledge of this perplexing condition.

Not far behind is Massachusettsf Pennsylvania leads with an impressive seven active trials focused on frontotemporal dementia, accompanied by a total of 23 trials in their journey thus far. Their pioneering efforts began back in 2003 when they recorded their first trial dedicated to understanding this debilitating disease. Similarly committed to advancing research is Mayo Clinic in Rochester, where six ongoing clinical trials are shedding light on frontotemporal dementia. With a history encompassing 15 previously conducted studies since their inaugural trial in 2008, Mayo Clinic continues to push boundaries and expand our knowledge of this perplexing condition.

Not far behind is Massachusetts General Hospital located amidst Boston's medical hub that actively engages with four current frontotemporal dementia trials while boasting ten successful past investigations from as recent as2011 onwards; proving its dedication towards unraveling mysteries surrounding this disorder.Johns Hopkins Hospital based out of Baltimore also joins the ranks with four active clinical tests underway for frontotemporal dementia care-needs along with notable contribution having accomplished five previous experiments starting revelations through it's initial study undertaken at around2007 inception.Furthermore,the University of California San Francisco demonstrates its commitment by conducting three ongoing clinical trials aimed at investigating frontotemporal dementia, adding insights sourced from seven prior studies initiated since recording their first trial just aboutseven years ago,in2014.

The tireless efforts showcased by these leading institutions emphasize not only progress but promise for individuals affected by frontotemporal dementia worldwide. Each study serves as a stepping-stone toward breakthroughs that can potentially enhance patient outcomes and improve quality of life for those living with this challenging condition

Which are the best cities for frontotemporal dementia clinical trials?

When it comes to frontotemporal dementia clinical trials, several cities stand out for their research efforts. San Francisco, California leads the way with 11 active trials focusing on treatments like AL001 and Care Ecosystem. Philadelphia, Pennsylvania, California leads the way with 11 active trials focusing on treatments like AL001 and Care Ecosystem. Philadelphia, Pennsylvania follows closely behind with 10 ongoing studies exploring interventions such as Online training sites and Low-Intensity Prompts. Rochester, Minnesota is another notable city with 9 active trials investigating therapies like Algorithmically Matched approaches and Pittsburgh Compound B (C-11 PiB). These cities, along with Baltimore, Maryland and Toronto, Ontario offer individuals affected by frontotemporal dementia access to cutting-edge clinical trials that contribute to advancements in care for this challenging condition.

Which are the top treatments for frontotemporal dementia being explored in clinical trials?

Frontotemporal dementia, a complex neurological disorder, is the focus of intensive clinical research. Currently, two treatments are making waves in active trials. AL001 takes the lead with its involvement in two ongoing studies and three all-time frontotemporal dementiae all-time frontotemporal dementia trials since 2018. Additionally, bilateral subgenual cingulate deep brain stimulation (SGC DBS) and Care Ecosystem have both recently entered the scene with one active trial each and first listings in 2023. As researchers delve deeper into understanding this challenging condition, these innovative approaches hold promise for improving treatment outcomes for individuals affected by frontotemporal dementia.

What are the most recent clinical trials for frontotemporal dementia?

Exciting developments are underway in the field of frontotemporal dementia, with recent clinical trials offering hope for improved treatments. One trial is examining the effects of remotely supervised tDCS (transcranial direct current stimulation) combined with word-naming practice as a potential intervention. Another study is investigating the use of N-Acetyl-L-Leucine, aiming to determine its efficacy in treating frontotemporal dementiad tDCS (transcranial direct current stimulation) combined with word-naming practice as a potential intervention. Another study is investigating the use of N-Acetyl-L-Leucine, aiming to determine its efficacy in treating frontotemporal dementia. Additionally, verdiperstat is being evaluated in a Phase 1 trial to assess its impact on this neurodegenerative disorder. These innovative trials provide valuable insights and hold promise for advancing our understanding and treatment options for individuals affected by frontotemporal dementia.

What frontotemporal dementia clinical trials were recently completed?

In the realm of frontotemporal dementia research, a notable clinical trial investigating the potential of Lithium Carbonate has recently concluded. Sponsored by Columbia University, this trial reached completion in January 2017. While more recent trials may be underway or pending results, this study represents an important effort to advance our understanding and treatment options for frontotemporal dementia.